Alkermes Plc (ALKS) — Quality & forensics
As of 2026-09-18 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.
The Closelook module scores
- Valuation 23
- Quality 51
- Growth 45
- Balance sheet 85
- Cash quality 65
- Capital allocation 37
- Momentum 75
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the ALKS chart & overview · the earnings record
FAQ · from the current data · as of 2026-09-18
Quick answers
What is Alkermes Plc's Closelook quality reading?
The composite reads 53/100 across 7 modules, as of 2026-09-18: valuation 23, quality 51, growth 45, balance sheet 85, cash quality 65, capital allocation 37, momentum 75. Closelook scores are research diary readings, not ratings or investment advice.
What is Alkermes Plc's Altman Z-Score?
7.69, which sits in the safe zone (above 2.99) as of 2026-09-18. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Alkermes Plc's Piotroski F-Score?
6 of 8, as of 2026-09-18. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Alkermes Plc's Beneish M-Score indicate?
-3.54 — below the −1.78 manipulation-risk threshold, as of 2026-09-18. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelook universe
then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- AMRX Amneal Pharmaceuticals, Inc. Class A Common Stockindustry
- BHC.TO Bausch Health Companies Incindustry
- ALM.MC Almirall S.A.industry
- FAGR.BR Fagron NVindustry
- TAK Takeda Pharmaceutical Co Ltd ADRindustry
- APTX.TO Apotex Health Corpindustry
- HCM.L HUTCHMED China Ltdindustry
- PRGO Perrigo Company PLCindustry
- KNSA Kiniksa Pharmaceuticals Ltdindustry
- VTRS Viatris Incindustry
- LNTH Lantheus Holdings Incindustry
- NBIX Neurocrine Biosciences Incindustry
- LQDA Liquidia Technologies Incindustry
- ROVI.MC Laboratorios Farmaceuticos ROVIindustry
- RDY Dr. Reddy’s Laboratories Ltd ADRindustry
- ZTS Zoetis Incindustry
- DMP.DE Dermapharm Holding SEindustry
- UTHR United Therapeutics Corporationindustry
- ELAN Elanco Animal Healthindustry
- HIMS Hims Hers Health Incindustry